



# CDK inhibitors

2009




FRINNOV

[www.frinnov.fr](http://www.frinnov.fr)

# "IP Overview – CDK Inhibitors"

## *Patent global landscape as a new tool to decipher market trends*

One of the most exciting developments in the 90's has been the elucidation of the molecular mechanisms that control the progression of cells through the division cycle. The cell-cycle progression is composed of two main phases, interphase and mitosis. It is controlled by a set of kinases in which cyclin dependent kinases (CDK) play a major role in triggering the cell cycle transitions.



Alterations in CDK activity have been associated in the development of viral infections, neurodegenerative disorders such as Alzheimer's disease and proliferative diseases such as renal diseases and cancers. These observations led the CDK family to become a central target for the development of new therapies.

During the last two decades, evolution of patent filings of CDK inhibitors shows two major phases. A strong increase until 2002 is associated with the capacity of CDK inhibitors to target a large number of diseases. Results of advanced clinical stages confirm the potential of these compounds but emphasize new challenges in order to reach marketable products. A significant decrease follows until 2005 when a new generation of CDK inhibitors takes the lead in R&D interest.

This IP Overview provides you with a comprehensive panorama of the intellectual property landscape of this new and promising sector and helps you:

- Position your company's R&D and IP Portfolio
- Identify key inventors and key players involved in specific thematic
- Understand the collaboration networks and their dynamics
- Uncover trends and emerging segments

# Contents

<b>METHODOLOGY</b>	<b>7</b>
<b>INTRODUCTION</b>	<b>8</b>
<b>1. BRIEF OUTLINE OF THE PIPELINE</b>	<b>12</b>
<b>2. PROTECTION STRATEGIES</b>	<b>13</b>
2.1. Evolution of patent filings over time	13
2.2. Priority filings	14
2.3. Extensions	15
2.4. Analysis of industrial patents over time	17
2.5. Study of the granting of US patents	18
2.6. Study of the granting of European patents	20
2.7. Evolution in the number of applicants	21
<b>3. TOPOLOGY OF PATENTS IN THE SECTOR</b>	<b>23</b>
3.1. Breakdown of patents into classes of CDK inhibitors	23
3.2. Breakdown of patents into types of targeted CDK	29
3.3. Cross analysis of the categories “classes of CDK inhibitors” and “types of targeted CDK”	32
<b>4. ANALYSIS OF THE MAIN APPLICANTS</b>	<b>34</b>
4.1. Main applicants	34
4.2. Filings by main applicants over time	37
4.3. Focus on the global strategy of the major industrial applicants	38
4.4. Topics protected	46
4.5. Collaborations	51
4.6. Citations between applicants	53
4.7. Emerging applicants	55
<b>5. ANALYSIS OF THE MAIN INVENTORS</b>	<b>56</b>
5.1. Main inventors	56
5.2. Topics protected	58
5.3. Research teams	62
5.4. Experts	64
5.5. Emerging inventors	65
<b>CONCLUSION</b>	<b>66</b>
<b>APPENDIX 1: APPLICANTS WITH ACTIVE CLINICAL TRIALS AND THEIR NUMBER OF PATENT FILINGS</b>	<b>68</b>
<b>APPENDIX 2: PATENT FILINGS OF APPLICANTS BY MAIN TOPICS</b>	<b>69</b>
<b>APPENDIX 3: NUMBER OF PATENT FILINGS PER APPLICANTS</b>	<b>79</b>

# List of Figures

<b>FIGURE 1 - SCHEMATIC REGULATION OF THE CDK-CYCLIN COMPLEX</b>	<b>9</b>
<b>FIGURE 2 - THE CELL CYCLE AND ITS REGULATION BY CDK</b>	<b>9</b>
<b>FIGURE 3 - CDK INHIBITORS UNDER DEVELOPMENT BY CLASS OF COMPOUNDS (AUGUST 2009)</b>	<b>12</b>
<b>FIGURE 4 - EVOLUTION IN PATENT FILINGS</b>	<b>13</b>
<b>FIGURE 5 - GEOGRAPHIC DISTRIBUTION OF PRIORITY FILINGS</b>	<b>14</b>
<b>FIGURE 6 - GEOGRAPHIC DISTRIBUTION OF EXTENSIONS</b>	<b>16</b>
<b>FIGURE 7 - EVOLUTION OF THE BREAKDOWN OF INDUSTRIAL PATENTS</b>	<b>17</b>
<b>FIGURE 8 - EVOLUTION OF AVERAGE GRANT TIME FOR US PATENTS</b>	<b>18</b>
<b>FIGURE 9 - EVOLUTION OF THE GRANTING OF US PATENTS</b>	<b>19</b>
<b>FIGURE 10 - EVOLUTION OF AVERAGE GRANT TIME FOR EUROPEAN PATENTS</b>	<b>20</b>
<b>FIGURE 11 - EVOLUTION OF AVERAGE GRANT TIME FOR EUROPEAN PATENTS</b>	<b>21</b>
<b>FIGURE 12 - EVOLUTION OF THE NUMBER OF APPLICANTS</b>	<b>22</b>
<b>FIGURE 13 - BREAKDOWN OF THE PORTFOLIO BY CLASSES OF COMPOUNDS</b>	<b>24</b>
<b>FIGURE 14 - BREAKDOWN OF THE PORTFOLIO BY TYPES OF TARGETED CDK</b>	<b>30</b>
<b>FIGURE 15 - CROSS-ANALYSIS OF THE CATEGORIES "CLASSES OF CDK INHIBITORS" AND "TYPES OF TARGETED CDK"</b>	<b>33</b>
<b>FIGURE 16 - MAIN APPLICANTS IN THE ENTIRE PORTFOLIO</b>	<b>34</b>
<b>FIGURE 17 - BREAKDOWN OF THE MAIN PATENT PORTFOLIOS</b>	<b>35</b>
<b>FIGURE 18 - EXTENSION POLICY FOR THE FIVE MAJOR INDUSTRIAL PLAYERS</b>	<b>36</b>
<b>FIGURE 19 - CLASSES OF CDK INHIBITORS BY MAIN APPLICANTS</b>	<b>47</b>
<b>FIGURE 20 - TYPES OF TARGETED CDK BY MAIN APPLICANTS</b>	<b>48</b>
<b>FIGURE 21 - MAIN PLAYERS POSITIONED ON THE DEVELOPMENT OF SCREENING METHODS, COMBINATIONS AND OLIGONUCLEOTIDES (&gt;3 FILINGS)</b>	<b>49</b>
<b>FIGURE 22 - MAJOR COLLABORATIONS AND JOINT-FILINGS</b>	<b>52</b>
<b>FIGURE 23 - MAP OF CITATIONS BETWEEN APPLICANTS</b>	<b>54</b>
<b>FIGURE 24 - CLASSES OF CDK INHIBITORS BY MAIN INVENTORS</b>	<b>59</b>
<b>FIGURE 25 - TYPES OF TARGETED CDK BY MAIN INVENTORS</b>	<b>60</b>
<b>FIGURE 26 - MAIN RESEARCH TEAM</b>	<b>63</b>
<b>FIGURE 27 - LIST OF EXPERT</b>	<b>64</b>

# List of Tables

<b>TABLE 1 - CYCLIN DEPENDENT KINASES INVOLVED IN DISEASES OR REPRODUCTION</b>	<b>10</b>
<b>TABLE 2 - EVOLUTION OF PRIORITY FILINGS</b>	<b>15</b>
<b>TABLE 3 - EVOLUTION OF EXTENSIONS</b>	<b>16</b>
<b>TABLE 4 - DESCRIPTION OF THE CLASSES OF COMPOUNDS USED TO BREAK DOWN THE PORTFOLIO</b>	<b>23</b>
<b>TABLE 5 - BREAKDOWN BY CLASSES OF CDK INHIBITORS OVER TIME</b>	<b>25</b>
<b>TABLE 6 - BREAKDOWN BY SCREENING METHODS, COMBINATIONS AND OLIGONUCLEOTIDES OVER TIME</b>	<b>25</b>
<b>TABLE 7 - BREAKDOWN BY CLASSES OF CDK INHIBITORS OVER TIME</b>	<b>31</b>
<b>TABLE 8 - BREAKDOWN OF FILINGS BY MAIN APPLICANTS OVER TIME</b>	<b>37</b>
<b>TABLE 9 - EMERGING APPLICANTS</b>	<b>55</b>
<b>TABLE 10 -LIST OF THE MAIN INVENTORS</b>	<b>58</b>
<b>TABLE 11 -EMERGING INVENTORS</b>	<b>65</b>

# ORDER FORM

Complete, sign and send this order form by email [ipoverview@fist.fr](mailto:ipoverview@fist.fr) or by fax +33 (0) 1 40 51 78 58  
or purchase your report directly on line <http://www.frinnov.fr>

## Delivery Information

Title: ..... Last Name: ..... First Name: .....  
Company: .....  
Email: ..... Phone: .....  
Address: .....  
.....  
Zip: ..... City: ..... Country: .....

Overview

## Billing address (if different)

.....  
.....  
.....

I hereby state that I have the authority to place orders for the above mentioned company (if applicable) and accept and understand Frinnov's Terms and Conditions of Sale accessible on line: <http://www.frinnov.fr>

Date: ..... Signature: .....

Please take my order for the following report

Qty	Description	Price Ea.	Total
1	IP Overview "CDK Inhibitor"	1 125,00 €	1 125,00 €
		VAT (19.6%)	220,50 €
		<b>Total</b>	<b>1 345,50 €</b>

## Payment method

- Cheque payable to FIST and sent to FIST SA, 83 Bd Exelmans, FR-75016 Paris
- Bank transfer: BNP Paribas, Paris AG-Centrale Entreprises, Bank code: 30004, Branch code: 00818, Account No: 00021375689 27

RIB : 30004 00818 00021375689 27  
IBAN : FR76 3000 4008 1800 0213 7568 927  
SWIFT / BIC : BNPAFRPPVD

For EU Member (outside France), kindly state your VAT number: .....



**FRINNOV**

[www.frinnov.fr](http://www.frinnov.fr)